颐和春胶囊对少弱精子症治疗效果的临床观察

Therapeutic effect of Yihechun Capsules on oligozoospermia and asthenospermia

目的:观察颐和春胶囊对少弱精子症患者的治疗效果。方法:选取因少弱精子症而导致不育的181例患者,随机分为治疗组93例(其中少精子症者42例,弱精子症者20例,少弱精子症者31例)给予颐和春胶囊(4粒/d,2次/d)联合左卡尼汀口服液(2~3 g/d,早、晚2次或早、中、晚3次用餐时口服);对照组88例(其中少精子症者39例,弱精子症者22例,少弱精子症者27例)仅使用左卡尼丁口服液,用法与治疗组相同。治疗3个月后,对比两组的精子浓度、a级精子百分率、(a+b)级精子百分率以及配偶妊娠率。结果:181例患者中,治疗组有5例,对照组有2例因未遵医嘱规律服药而计入脱落病例。治疗前,两组患者的精子浓度、a级精子百分率及(a+b)级精子百分率的差异均无统计学意义(P>0.05);治疗后两组各亚组精子浓度和活力均比治疗前显著增加(P<0.05)。治疗后,治疗组与对照组比较,少精子症者精子浓度[(21.07±6.98)×10^6/ml vs(16.56±1.82)×10^6/ml]、a级精子百分率[(27.53±3.34)%vs(26.88±1.35)%]、(a+b)级精子百分率[(53.32±3.16)%vs(52.63±2.48)%],弱精子症者精子浓度[(26.36±3.37)×10^6/ml vs(24.42±2.21)×10^6/ml]、a级精子百分率[(25.28±4.64)%vs(21.32±3.28)%]、(a+b)级精子百分率[(49.19±2.87)%vs(45.64±1.78)%],少弱精子者精子浓度[(19.38±3.39)×10^6/ml vs(18.75±1.35)×10^6/ml]、a级精子百分率[(22.65±4.81)%vs(21.31±2.42)%]、(a+b)级精子百分率[(48.74±5.61)%vs(44.36±1.32)%]均增加更显著(P<0.05)。治疗组患者配偶的妊娠率为36.4%(32/88),显著高于对照组[15.1%(13/86)],P<0.01]。结论:颐和春胶囊联合左卡尼丁口服液治疗少弱精子症效果明显。

Objective:To observe the clinical effect of Yihechun Capsules(YHC)on oligozoospermia and asthenospermia.Methods:A total of 181 male patients with infertility were randomly divided into a YHC+Levocarnitine(LC)group(n=93,including 42 cases of oligozoospermia,20 cases of asthenospermia and 31 cases of oligoasthenospermia)and an LC control group(n=88,including 39 cases of oligozoospermia,22 cases of asthenospermia and 27 cases of oligoasthenospermia),the former treated with YHC([0.3 g per capsule],once 4 capsules,bid,30 minutes after meal)combined with LC oral liquid(2-3 g/d,tid,at mealtime)and the latter with LC oral liquid only(2-3 g/d,tid,at mealtime).After 3 months of treatment,comparisons were made between the two groups of patients in sperm concentration,the percentages of grade a and grade a+b sperm,and the rate of pregnancy.Results:Of the 181 patients,5 in the YHC+LC group and 2 in the LC control group failed to complete the course of treatment.There were no statistically significant differences between the two groups of patients in the baseline sperm concentration and the percentages of grade a and grade a+b sperm(P>0.05),wich were all markedly increased in both the YHC+LC and the LC control groups(P<0.05)after 3 months of treatment.And the patients of the YHC+LC group,compared with the controls,showed even more significant increases,as the oligozoospermia patients in sperm concentration([21.07±6.98]vs[16.56±1.82]×10^6/ml,P<0.05)and the percentages of grade a sperm([27.53±3.34]%vs[26.88±1.35]%,P<0.05)and grade a+b sperm([53.32±3.16]%vs[52.63±2.48]%,P<0.05),the asthenospermia patients in sperm concentration([26.36±3.37]vs[24.42±2.21]×10^6/ml,P<0.05)and the percentages of grade a sperm([25.28±4.64]%vs[21.32±3.28]%,P<0.05)and grade a+b sperm([49.19±2.87]%vs[45.64±1.78]%,P<0.05),and the oligoasthenospermia patients in sperm concentration([19.38±3.39]vs[18.75±1.35]×106/ml,P<0.05)and the percentages of grade a sperm([22.65±4.81]%vs[21.31±2.42]%,P<0.05)and grade a+b sperm([48.74±5.61]%vs[44.36±1.32]%,P<0.05).The pregnancy rate was dramatically higher in the YHC+LC than in the LC control group(36.4%[32/88]vs 15.1%[13/86],P<0.01).Conclusion:Yihechun Capsules combined with Levocarnitine oral liquid is evidently effective for the treatment of oligozoospermia and asthenospermia.